CD274 and pneumonitis: Previous prospective and retrospective studies revealed that the occurrence of all grade treatment‐related pneumonitis varied from 8.2% to 33.9% with grade≥3 pneumonitis ranging from 3.4% to 11.1% in patients with lung cancer receiving PD‐(L)1 inhibitor treatment concurrently combined with TRT or sequentially with a history of TRT, which was considered tolerable overall.2, 9, 21, 22, 23